Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks.
Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must assume that since then it has been too busy to build a company website…
Nonetheless, operating out of the MS Ventures Israel BioIncubator in Yavne, Metabomed is focusing on the discovery and development of small molecule drugs directed against novel targets in the field of cancer metabolism.
This is based on its proprietary target identification platform, which allows the pinpointing of new genes that form a ‘synthetic lethal gene pair’ with metabolic genes (inactivated in cancer cells) – making cancer cells non-viable.
Now, Metabomed has raised around €15.8M ($18M) from both previous investors and new investors –